Since the eighties, biosimilar medicines have played an increasingly important role in health: a market that moves around €1,000 million
Advanced therapies and biosimilars are becoming an increasingly attractive option for reducing the economic burden faced by health systems
The European Union has pioneered the approval of around forty biosimilars up to 2017